Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.41 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.41 |
| ▸ | ITGAL | P20701 | 2/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL563862 | 1.00 | HSD11B1 (0.50) | HSD11B1LMNACA12CA1CA2 | |
| SCHEMBL9728079 | 0.85 | ACE (0.46) | HSD11B1LMNACA12CA1CA2 | |
| SCHEMBL10078336 | 0.80 | LMNA (0.48) | LMNACA12CA1CA2CA3 | |
| SCHEMBL7298731 | 0.79 | HSD11B1 (0.43) | HSD11B1ITGB2ICAM1ITGALROCK2 | |
| SCHEMBL7296204 | 0.79 | HSD11B1 (0.43) | HSD11B1ITGB2ICAM1ITGALROCK2 | |
| SCHEMBL2353660 | 0.79 | LMNA (0.50) | LMNACA12CA1CA2CA3 | |
| SCHEMBL10078325 | 0.79 | LMNA (0.50) | LMNACA12CA1CA2CA3 | |
| SCHEMBL23927406 | 0.78 | CA1 (0.49) | LMNACA12CA1CA2CA3 | |
| SCHEMBL563868 | 0.77 | LMNA (0.46) | LMNACA12CA1CA2CA3 | |
| SCHEMBL14177569 | 0.76 | HSD11B1 (0.51) | HSD11B1ROCK2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492416-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2013-07-23 | — | — | US | disclosed |
| US-20120035239-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB Biopharma SRL (BE) | 2012-02-09 | — | — | US | disclosed |
| US-8034958-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UOB Pharma, S.A. (BE) | 2011-10-11 | — | — | US | disclosed |
| US-20100222576-A1 | 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB BIOPHARMA SPRL (BE) | 2010-09-02 | — | — | US | disclosed |
| US-7692028-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2010-04-06 | — | — | US | disclosed |
| US-20080097109-A1 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB BIOPHARMA SPRL (BE) | 2008-04-24 | — | — | US | disclosed |
| US-20050171187-A1 | 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | DIFFERDING EDMOND (BE) | 2005-08-04 | — | — | US | disclosed |
| US-6911461-B2 | For treating epilepsy, epileptogenesis, seizure disorders, convulsions, bipolar disorders, mania, depression, anxiety, migraine, neuralgia, chronic pain, neuropathic pain, cerebral ischemia, cardiac arrhythmia, myotonia, cocaine abuse | UCB, S.A. (BE) | 2005-06-28 | — | — | US | disclosed |
| US-6806287-B2 | NEUROLOGICAL DISORDERS; SUCH AS 2-(4-(2,2-DIFLUOROVINYL)-2-OXOPYRROLIDINYL)BUTANAMIDE | UCB, S.A. (BE) | 2004-10-19 | — | — | US | disclosed |
| US-6784197-B2 | SUCH AS (2S)-2-((4S)-4-(2,2-DIFLUOROVINYL)-2-OXOPYRROLIDINYL) BUTANAMIDE; ANTIEPILEPTIC AGENTS; ANTICONVULSANTS | UCB S.A. (BE) | 2004-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171187-A1 | 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | CYP1B1, OGDH, CYP1A2 | HSD11B1 670/4885LMNA 3694/4885CA12 4426/4885 |
| US-20080097109-A1 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | CYP1B1, OGDH, CYP1A2 | HSD11B1 670/4885LMNA 3694/4885CA12 4426/4885 |
| US-20100222576-A1 | 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | CYP1B1, OGDH, CYP1A2 | HSD11B1 670/4885LMNA 3694/4885CA12 4426/4885 |
| US-20120035239-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | CYP1B1, OGDH, CYP1A2 | HSD11B1 670/4885LMNA 3694/4885CA12 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.